Immunodiscordant responses to HAART – mechanisms and consequences

References

• Autran B. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277(5322), 112–116 (1997).
   PubMed Web of Science ®Google Scholar
• Pakker NG, Notermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4(2), 208–214 (1998).
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Clise-Dwyer K, Huston GE et al. Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc. Natl Acad. Sci. USA 106(43), 18333–18338 (2009).
   Google Scholar
• Mocroft A, Phillips AN, Gatell J et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370(9585), 407–413 (2007).
   PubMed Web of Science ®Google Scholar
• Hunt PW, Deeks SG, Rodriguez B et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17(13), 1907–1915 (2003).
   Google Scholar
• Pacheco YM, Jarrín I, del Amo J et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr. HIV Res. 7(6), 612–619 (2009).
   Google Scholar
• Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 44(3), 441–446 (2007).
   PubMed Web of Science ®Google Scholar
• Robbins GK, Spritzler JG, Chan ES et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS clinical trials group protocol 384. Clin. Infect. Dis. 48(3), 350–361 (2009).
   Google Scholar
• Piketty C, Castiel P, Belec L et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (Lond.) 12(7), 745–750 (1998).
   PubMed Web of Science ®Google Scholar
• Kelley CF, Kitchen CMR, Hunt PW et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48(6), 787–794 (2009).
   PubMed Web of Science ®Google Scholar
• Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in hiv infection: mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol. 2012, 1–17 (2012).
   Google Scholar
• Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133(6), 401–410 (2000).
   PubMed Web of Science ®Google Scholar
• Florence E, Lundgren J, Dreezen C et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 4(3), 255–262 (2003).
   PubMedGoogle Scholar
• Kaufmann GR, Perrin L, Pantaleo G et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163(18), 2187–2195 (2003).
   PubMedGoogle Scholar
• Kaufmann GR, Furrer H, Ledergerber B et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 Cells/mL in HIV type 1–infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41(3), 361–372 (2005).
   PubMed Web of Science ®Google Scholar
• Lewden C, Chene G, Morlat P et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune. Defic. Syndr. 46(1), 72–77 (2007).
   PubMed Web of Science ®Google Scholar
• Baker JV, Peng G, Rapkin J et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J. Acquir. Immune. Defic. Syndr. 48(5), 541–546 (2008).
   PubMed Web of Science ®Google Scholar
• Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin. Infect. Dis. 47(8), 1102–1104 (2008).
   PubMed Web of Science ®Google Scholar
• The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 9(3), e1001194 (2012).
   Google Scholar
• Gazzola L, Tincati C, Bellistrì GM, Monforte AD, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis. 48(3), 328–337 (2009).
   PubMed Web of Science ®Google Scholar
• AIDSinfo. HIV/AIDS Guidelines. 1–240 (2012).
   Google Scholar
• Isgrò A, Aiuti A, Leti W et al. Immunodysregulation of HIV disease at bone marrow level. Autoimmun. Rev. 4(8), 486–490 (2005).
   Google Scholar
• Isgrò A, Leti W, De Santis W et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin. Infect. Dis. 46(12), 1902–1910 (2008).
   Google Scholar
• Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396(6712), 690–695 (1998).
   PubMed Web of Science ®Google Scholar
• Smith KY, Valdez H, Landay A et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J. Infect. Dis. 181(1), 141–147 (2000).
   Google Scholar
• Franco JM, Rubio A, Martínez-Moya M et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 99(10), 3702–3706 (2002).
   Google Scholar
• Ruiz-Mateos E, Rubio A, Vallejo A et al. Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART). Clin. Exp. Immunol. 136(3), 501–506 (2004).
   Google Scholar
• Vrisekoop N, van Gent R, de Boer AB et al. Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging. J. Immunol. 181(2), 1573–1581 (2008).
   Google Scholar
• Teixeira L, Valdez H, McCune JM et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 15(14), 1749–1756 (2001).
   Google Scholar
• Tanaskovic S, Fernandez S, French MA et al. Thymic tissue is not evident on high-resolution computed tomography and [18F]fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4+ T cells. AIDS (Lond.) 25(9), 1235–1237 (2011).
   Google Scholar
• Benveniste O, Flahault A, Rollot F et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J. Infect. Dis. 191(10), 1670–1679 (2005).
   Google Scholar
• Marchetti G, Gori A, Casabianca A et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20(13), 1727–1736 (2006).
   Google Scholar
• Massanella M, Negredo E, Pérez-Álvarez N et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS (Lond.) 24(7), 959–968 (2010).
   PubMed Web of Science ®Google Scholar
• Lederman MM, Calabrese L, Funderburg NT et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204(8), 1217–1226 (2011).
   PubMedGoogle Scholar
• Marziali M, De Santis W, Carello R et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 20(16), 2033–2041 (2006).
   PubMed Web of Science ®Google Scholar
• Molina-Pinelo S, Vallejo A, Díaz L et al. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J. Antimicrob. Chemother. 64(3), 579–588 (2009).
   Google Scholar
• Okoye AA, Rohankhedkar M, Abana C et al. Naive T cells are dispensable for memory CD4+ T cell homeostasis in progressive simian immunodeficiency virus infection. J. Exp. Med. 209(4), 641–651 (2012).
   Google Scholar
• Douek DC, Betts MR, Hill BJ et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J. Immunol. 167(11), 6663–6668 (2001).
   Google Scholar
• Anthony KB, Yoder C, Metcalf JA et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J. Acquir. Immune. Defic. Syndr. 33(2), 125–133 (2003).
   Google Scholar
• Catalfamo M, Wilhelm C, Tcheung L et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J. Immunol. 186(4), 2106–2116 (2011).
   Google Scholar
• Catalfamo M, Di Mascio M, Hu Z et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc. Natl Acad. Sci. USA 105(50), 19851–19856 (2008).
   PubMed Web of Science ®Google Scholar
• Napolitano LA, Schmidt D, Gotway MB et al. Growth hormone enhances thymic function in HIV-1-infected adults. J. Clin. Invest. 118(3), 1085–1098 (2008).
   PubMed Web of Science ®Google Scholar
• Hodge JN, Srinivasula S, Hu Z et al. Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood 118(12), 3244–3253 (2011).
   Google Scholar
• Schacker TW, Nguyen PL, Beilman GJ et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J. Clin. Invest. 110(8), 1133–1139 (2002).
   Google Scholar
• Estes J, Baker JV, Brenchley JM et al. Collagen deposition limits immune reconstitution in the gut. J. Infect. Dis. 198(4), 456–464 (2008).
   Google Scholar
• Schacker TW, Reilly C, Beilman GJ et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 19(18), 2169 (2005).
   Google Scholar
• Hunt PW, Brenchley J, Sinclair E et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197(1), 126–133 (2008).
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187(10), 1534–1543 (2003).
   PubMed Web of Science ®Google Scholar
• Massanella M, Curriu M, Carrillo J et al. Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry A. 83(7), 648–658 (2013).
   Google Scholar
• Negredo E, Massanella M, Puig J et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin. Infect. Dis. 50(9), 1300–1308 (2010).
   PubMed Web of Science ®Google Scholar
• Kang I, Hong MS, Nolasco H et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J. Immunol. 173(1), 673–681 (2004).
   Google Scholar
• Marchetti G, Gazzola L, Trabattoni D et al. Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. AIDS (Lond.) 24(10), 1455–1460 (2010).
   Google Scholar
• Erikstrup C, Kronborg G, Lohse N, Ostrowski SR, Gerstoft J, Ullum H. T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication. J. Acquir. Immune. Defic. Syndr. 53(3), 303–310 (2010).
   Google Scholar
• Méndez-Lagares G, García-Pergañeda A, Del Mar Del Pozo-Balado M et al. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. J. Antimicrob. Chemother. 67(5), 1228–1237 (2012).
   Google Scholar
• Nakanjako D, Ssewanyana I, Mayanja-Kizza H et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect. Dis. 11(1), 43 (2011).
   PubMedGoogle Scholar
• Sennepin A, Baychelier F, Guihot A et al. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy. AIDS 27(12), 1857–1866 (2013).
   Google Scholar
• Gougeon M, Lecoeur H, Dulioust A et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156(9), 3509 (1996).
   PubMed Web of Science ®Google Scholar
• Arnoult D, Petit F, Lelièvre JD et al. Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ. 10(11), 1240–1252 (2003).
   Google Scholar
• Kolte L, Gaardbo JC, Skogstrand K, Ryder LP, Ersbøll AK, Nielsen SD. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs. Clin. Exp. Immunol. 155(1), 44–52 (2009).
   Google Scholar
• Méndez-Lagares G, Pozo-Balado MM, Del Mar Del Pozo-Balado M et al. Severe immune dysregulation affects CD4? CD25(hi)FoxP3? regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J. Infect. Dis. 205(10), 1501–1509 (2012).
   Google Scholar
• Kotler DP. Characterization of intestinal disease associated with human immunodeficiency virus infection and response to antiretroviral therapy. J. Infect. Dis. 179 (Suppl. 3), S454–S456 (1999).
   Google Scholar
• McGowan I, Elliott J, Fuerst M et al. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J. Acquir. Immune. Defic. Syndr. 37(2), 1228–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Kotler DP, Reka S, Clayton F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig. Dis. Sci. 38(6), 1119–1127 (1993).
   Google Scholar
• Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434(7037), 1093–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J. Virol. 81(2), 599–612 (2007).
   PubMed Web of Science ®Google Scholar
• Guadalupe M, Reay E, Sankaran S et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77(21), 11708–11717 (2003).
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365–1371 (2006).
   PubMed Web of Science ®Google Scholar
• Marchetti G, Bellistrì GM, Borghi E et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS (Lond.) 22(15), 2035–2038 (2008).
   Web of Science ®Google Scholar
• Jiang W, Lederman MM, Hunt P et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199(8), 1177–1185 (2009).
   PubMed Web of Science ®Google Scholar
• Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105(10), 3879–3884 (2008).
   PubMed Web of Science ®Google Scholar
• Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122(1), 22–28 (2008).
   PubMed Web of Science ®Google Scholar
• Mavigner M, Delobel P, Cazabat M et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 4(10), e7658 (2009).
   PubMed Web of Science ®Google Scholar
• Negredo E, Massanella M, Puertas MC et al. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J. Antimicrob. Chemother. 68(10), 2358–2362 (2013).
   Google Scholar
• Chun T-W, Nickle DC, Justement JS et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197(5), 714–720 (2008).
   PubMed Web of Science ®Google Scholar
• Yukl SA, Gianella S, Sinclair E et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 202(10), 1553–1561 (2010).
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Massanella M, Llibre JM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16(4), 460–465 (2010).
   PubMed Web of Science ®Google Scholar
• Chomont N, El-Far M, Ancuta P et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15(8), 893–900 (2009).
   PubMed Web of Science ®Google Scholar
• Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin. Infect. Dis. 41(5), 713–720 (2005).
   PubMed Web of Science ®Google Scholar
• Körner C, Tolksdorf F, Riesner K et al. Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients. Antivir. Ther. (Lond.) 16(7), 1047–1055 (2011).
   PubMed Web of Science ®Google Scholar
• Körner C, Krämer B, Schulte D et al. Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin. Sci. 116(12), 861–870 (2009).
   Google Scholar
• Núñez M, Soriano V, López M et al. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin. Infect. Dis. 43(9), 1209–1212 (2006).
   Google Scholar
• Taya N, Torimoto Y, Shindo M, Hirai K, Hasebe C, Kohgo Y. Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br. J. Haematol. 110(1), 89–97 (2000).
   PubMed Web of Science ®Google Scholar
• Wood E, Montaner JSG, Yip B et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir. Ther. (Lond.) 9(2), 229–235 (2004).
   PubMed Web of Science ®Google Scholar
• Appay V, Fastenackels S, Katlama C et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (Lond.) 25(15), 1813–1822 (2011).
   PubMed Web of Science ®Google Scholar
• Negredo E, Moltó J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18(3), 459–463 (2004).
   PubMed Web of Science ®Google Scholar
• Haas DW, Geraghty DE, Andersen J et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. J. Infect. Dis. 194(8), 1098–1107 (2006).
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360(9327), 119–129 (2002).
   PubMed Web of Science ®Google Scholar
• Gutiérrez F, Padilla S, Masiá M et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr. HIV Res. 6(2), 100–107 (2008).
   Google Scholar
• Tan R, Westfall AO, Willig JH et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 47(5), 553–558 (2008).
   PubMed Web of Science ®Google Scholar
• Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J. Infect. Dis. 183(9), 1328–1335 (2001).
   Google Scholar
• Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JSG. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 20(3), 371–377 (2006).
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Genebat M, Moore D et al. A CD4+ cell count. J. Acquir. Immune. Defic. Syndr. 55(4), 451–459 (2010).
   Google Scholar
• van Lelyveld SFL, Gras L, Kesselring A et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS (Lond.) 26(4), 465–474 (2012).
   PubMed Web of Science ®Google Scholar
• , Strategies for Management of Antiretroviral Therapy (SMART) Study GroupEl-Sadr WM, Lundgren JD et al. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355(22), 2283–2296 (2006).
   Google Scholar
• Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect.Dis. 201(3), 318–330 (2010).
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141–155 (2011).
   PubMed Web of Science ®Google Scholar
• Odueyungbo A, Smieja M, Thabane L et al. Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study. AIDS Res. Ther. 6, 11 (2009).
   Google Scholar
• Ho JE, Scherzer R, Hecht FM et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS (Lond.)26(9), 1115–1120 (2012).
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker A, El-Sadr W et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J. Infect. Dis. 197(8), 1145–1155 (2008).
   Google Scholar
• Sopper S, Nierwetberg D, Halbach A et al. Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys. Blood 101(4), 1213–1219 (2003).
   PubMed Web of Science ®Google Scholar
• Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10(12), 1359–1365 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia F, Climent N, Guardo AC et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5(166), 166ra2–166ra2 (2013).
   PubMed Web of Science ®Google Scholar
• Grabmeier-Pfistershammer K, Stein D, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J. Acquir. Immune. Defic. Syndr. 56(2), 118–124 (2011).
   Google Scholar
• Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206–210 (2009).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch RJ et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7(8), e1000321 (2010).
   Google Scholar
• Rieckmann P, Poli G, Fox CH, Kehrl JH, Fauci AS. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol. 147(9), 2922–2927 (1991).
   Google Scholar
• Byakwaga H, Kelly M, Purcell DFJ et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J. Infect. Dis. 204(10), 1532–1540 (2011).
   PubMed Web of Science ®Google Scholar
• Hatano H, Hayes TL, Dahl V et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis. 203(7), 960–968 (2011).
   PubMed Web of Science ®Google Scholar
• Yukl SA, Shergill AK, Mcquaid K et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS (Lond.) 24(16), 2451–2460 (2010).
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Puig J et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 26(18), 2285–2293 (2012).
   PubMed Web of Science ®Google Scholar
• Llibre JM, Buzon MJ, Massanella M et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir. Ther. (Lond). 17(2), 355–364 (2012).
   PubMed Web of Science ®Google Scholar
• Kolber MA, Saenz MO, Tanner TJ, Arheart KL, Pahwa S, Liu H. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clin. Immunol. 126(3), 315–321 (2008).
   Google Scholar
• Hunt PW, Shulman NS, Hayes TL et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 121(23), 4635–4646 (2013).
   PubMed Web of Science ®Google Scholar
• Fletcher C. Pharmacologic Analysis of Lymphatic Reservoirs of HIV Infection. HIV Persistence During Therapy Workshop. St Maarten, WI, 6–9 December 2011, 7(Suppl. 2).
   Google Scholar
• Hatano H, Strain MC, Scherzer R et al. Increase in 2-LTR circles after raltegravir intensification in HAART-suppressed patients with high CD4+ T Cell counts: a randomized, controlled trial. Presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA, 3–6 March 2013.
   Google Scholar
• Kovacs JA, Vogel S, Albert JM et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335(18), 1350–1356 (1996).
   PubMed Web of Science ®Google Scholar
• ; INSIGHT-ESPRIT Study Group, SILCAAT Scientific CommitteeAbrams D, Lévy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16), 1548–1559 (2009).
   PubMed Web of Science ®Google Scholar
• Marchetti G, Meroni L, Varchetta S et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J. Infect. Dis. 186(5), 606–616 (2002).
   Google Scholar
• Weiss L, Letimier FA, Carriere M et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc. Natl Acad. Sci. USA 107(23), 10632–10637 (2010).
   Google Scholar
• Sereti I, Dunham RM, Spritzler J et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113(25), 6304–6314 (2009).
   PubMedGoogle Scholar
• Levy Y, Lacabaratz C, Weiss L et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119(4), 997–1007 (2009).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human thymus function. Blood 99(8), 2851–2858 (2002).
   Google Scholar
• Vandergeeten C, Fromentin R, DaFonseca S et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121(21), 4321–4329 (2013).
   PubMed Web of Science ®Google Scholar
• Smith K, Zheng L, Bosch R et al. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. AIDS Res. Hum. Retroviruses. 26(4), 425–432 (2010).
   Google Scholar
• Abrams DI, Shade SB, Couey P et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res. Hum. Retroviruses. 23(1), 77–85 (2007).
   PubMed Web of Science ®Google Scholar
• Kaur R, Bedimo R, Kvanli MB, Turner D, Shaw L, Margolis D. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res. Ther. 3, 16 (2006).
   Google Scholar
• Rizzardi GP, Vaccarezza M, Capiluppi B, Tambussi G, Lazzarin A, Pantaleo G. Cyclosporin A in combination with HAART in primary HIV-1 infection. J. Biol. Regul. Homeost. Agents 14(1), 79–81 (2000).
   PubMed Web of Science ®Google Scholar
• Havlir DV, Gilbert PB, Bennett K et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 15(11), 1379–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118(12), 3263–3272 (2011).
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J. Infect. Dis. 203(10), 1474–1483 (2011).
   PubMed Web of Science ®Google Scholar
• Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 214(2), 231–241 (2008).
   PubMed Web of Science ®Google Scholar